Markers bone resorption

Morabito et al., 2002 European postmenopause placebo, n = 30 genistein, n = 30 HRT, n = 30 First randomized, double-blind placebo-controlled study. Compared to placebo control, genistein (54 mg/day) consumed for 1 year significantly reduced urinary excretion of bone resorption markers and increased bone formation markers at 6 and 12 months BMD was significantly increased at the femoral neck and lumbar spine plasma genistein concentration was around 1.5 pM. HRT showed similar effects to genistein for BMD. 

Macdonald H, New S, Fraser W, Campbell M and Reid D. 2005. Low dietary potassium intakes and high dietary estimates of net endogenous acid production are associated with low bone mineral density in premenopausal women and increased markers of bone resorption in postmenopausal women. Am J Clin... 

A. Paget s disease is often asymptomatic and picked up on plain bone films. Patients with Paget s disease should have their serum calcium level determined to make sure that they are not hypercalcemic from excessive bone resorption, their serum alkaline phosphatase measured as a marker of new bone formation, a bone scan to determine whether other bones are involved, and a 24-hour urinary hy-droxyproUne measurement to assess bone resorption. The patient who has minimal involvement and is biochemically normal does not need pharmacological therapy. No studies indicate that early treatment slows progression in individuals with the more severe form of this disorder. 

Consumption of soy foods (providing 60mg/day isoflavones) for 12 weeks by postmenopausal women has been found to significantly decrease clinical risk factors for osteoporosis (short-term markers of bone turnover) including decreased urinary M-telopeptide excretion (bone resorption marker) and increased serum osteocalcin (bone formation marker). Furthermore, consumption of a soy isoflavone supplement containing 61.8 mg of isoflavones for 4 weeks by postmenopausal Japanese women significantly decreased excretion of bone resorption markers. ... 

Treatment with beclomethasone dipropionate 1500 micrograms/day for 6 weeks significantly reduced markers of bone formation (osteocalcin and PICP), whereas fluticasone propionate 750 micrograms/day had no effect. Neither drug affected biochemical markers of bone resorption. There was no significant change in bone density (SEDA-22,183). 

Wang C, Eyre DR, Clark R, Kleinberg D, Newman C, Iranmanesh A, Veldhuis J, Dudley RE, Berman N, Davidson T, Barstow TJ, Sinow R, Alexander G, Swerdloff RS. Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypo-gonadal men—a clinical research center study. J Clin Endocrinol Metab 1996 81(10) 3654-62. 

Rao, L.G., Collins, E.S., Josse, R.G., Strauss, A., and Rao, A.V. 2005. Lycopene consumption significantly decreases oxidative stress and bone resorption marker in postmenopausal women at risk of osteoporosis. Joint Meeting of the ECTS and IBMS June 25-29. Geneva, Switzerland. 

Fig. 12.3 Effects of daily teriparatide (TPTD) administration on biomarkers of bone formation (bone ALP and PICP) and bone resorption (DPD/Cr and NTx/Cr) in postmenopausal women with osteoporosis. Changes in bone formation markers at 1 month were significantly correlated with improvements in bone structure after 22 months of treatment (from [48]). 

The laboratory also measured biochemical markers of bone metabolism. The urinary excretion of deoxypyrolidone, a marker of bone resorption, was elevated (128 nmol/mmol creatinine normal is 31-110 nmol/mmol creatinine). Bone-specific alkaline phosphatase, a marker of bone synthesis, was also elevated at 400 U/L (normal is 70-139 U/L for girls between 3 and 8 years of age) (Tsai et al., 1999). The concentration of another marker of bone resorption, NTx (N-teleopeptide), in the patient s serum was elevated (110 nmol BCE/L normal is 20-68 nmol BCE/L [bone collagen equivalents]). 

Markers of bone resorption can be measured in serum or urine, whereas bone formation markers, such as bone-specific alkaline phosphatase, are usually measured in serum. Measurement of bone markers allows for real-time assessment of bone resorption or formation and can be used to monitor therapy (Ravn et al., 2003). The pyridonolines (deoxypyridinoline and pyridinoline) and the N- and C-teleopep-tides are the most frequently measured markers of bone resorption. Pyridinoline and teleopep-tides (NTx and CTx) are increased in individuals with metabolic bone diseases associated... 

Markers of bone formation produced by osteoblasts Markers of bone resorption produced by osteoclasts Products of collagen type I degradation... 

Tartrate-Resistant Acid Phosphatase, Marker of Bone Resorption (TRACP, EC.3.1.3.2 5-TRACP)... 

C8. Colwell, A., Russell, R. G., and Eastell, R., Factors affecting the assay of urinary 3-hydroxy pyridinium crosslinks of collagen as markers of bone resorption. Eur. J. Clin. Invest. 23, 341-349 (1993). 

P8. Popp-Snijders, C., Lips, P., and Netelenbos, J. C., Intra-individual variation in bone resorption markers in urine. Ann. Clin. Biochem. 33, 347-348 (1996). 

R6. Robins, S. P, Woitge, H., Hesley, R., Ju, J., Seyedin, S., and Seibel, M. J., Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J. Bone Miner. Res. 9, 1643-1649 (1994). 

W5. Woitge, H. W., Pecherstorfer, M., Li, Y., Keck, A. V., Horn, E., et al., Novel serum markers of bone resorption clinical assessment and comparison with established urinary indices. J. Bone Miner. Res. 14, 792-801 (1999). 

Clinical PK/PD Calcitonin has a well-established mechanism of action published literature supports that salmon calcitonin, mediated through calcitonin receptors located on osteoclasts, inhibits bone resorption, thereby increasing bone mineral density. Since serum beta-CTx (C-telopeptides of type 1 collagen, corrected for creatinine) is a recognized marker of bone resorption, the effect of administered salmon calcitonin on serum beta-CTx is considered to be an adequate surrogate for pharmacodynamic comparisons. 

---